SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

INOs FDA approval is prompting traders to speculate that the agency may be more receptive to rare-disease treatments, lifting attention on Capricor ahead of deramiocels FDA decision for Duchenne muscular dystrophy. The community is divided: some see the approval, recent data and launch-related hiring as encouraging signals, while others stress that CAPRs outcome is uncertain given prior FDA concerns and debate over the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put Precigens PAPZIMEOS in focus, prompting debate over the threat of new competition. Some traders worry about market share, while others argue Precigens first-mover advantage, commercial launch, and full approval temper the risk compared with Inovios accelerated approval.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline significantly during 2027 has fueled a sharp selloff, raising concerns about pricing and CorMedixs largest revenue driver. Traders disagree over whether DaVitas preliminary outlook signals lasting pressure, pointing to CMSs more reassuring payment estimate and arguing the reaction may be excessive.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report, fueled by demand for Mounjaro and Zepbound and a higher full-year revenue outlook, is driving LLYs rally and analyst upgrades. Bullish traders point to continued obesity-drug growth, while skeptics flag the trimmed profit outlook and high valuation.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure in a sharp semiconductor selloff as traders question whether heavy AI infrastructure spending will deliver sufficient returns, with weak Intel guidance and Amazons elevated capital spending adding to tech-sector jitters. The community is divided between warnings that AI-related investment and financing risks could prolong the decline and dip buyers pointing to strong demand and oversold conditions.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly results beat estimates, but declining user activity and a forecast for lower fourth-quarter bookings have driven a sharp selloff. Traders are largely bearish over slowing growth and monetization, while some view the drop as an overreaction and a buying opportunity.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BTGOs steep selloff and disappointing earnings are driving debate, with traders pointing to losses and weak share-price performance even as revenue and crypto-infrastructure activity grow. Bullish holders see potential in a Bitcoin recovery and expanding institutional custody business, while bears question the companys profitability and its failure to keep pace with other crypto stocks.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is drawing attention after a sharp selloff tied to Brazils election results and broader weakness in Brazilian-linked stocks. Traders disagree over whether political and market risks signal further downside or create a buying opportunity, with some pointing to the companys continued growth ahead of earnings.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas stronger-than-expected quarterly results and cost-savings plan to support drug development are driving attention, alongside CEO optimism about its pipeline. Traders are reacting to the sharp rise and move above the 200-day average with broadly bullish commentary.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook, alongside its positioning as an identity-security layer for AI agents, have fueled a sharp cybersecurity-led rally. Traders are divided over whether demand can justify the valuation, with some taking profits or betting on a pullback after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB...

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies.&nbsp;</li><li>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it.</li><li>A trial is now anticipated in July 2026, and milestone and royalty payments continue to be due to Anaptys during the proceedings.</li></ul><p>AnaptysBio, Inc. (ANAB) said on Friday that it has initiated litigation against GSK unit Tesaro, alleging a breach of the terms of the collaboration agreement between the two companies, inked in March 2014. This renewed battle adds to a fraught relationship between the two companies, with a trial now expected in July next year.</p><p><a href="https://stocktwits.com/symbol/ANAB">ANAB shares</a> dipped 10% in the pre-market session at the time of writing.</p><h2 class="st-heading-2">New Legal Fight</h2><p>Anaptys has<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary"> requested</a> that the court declare that Anaptys is entitled to all rights and remedies under the collaboration agreement. The company alleged that Tesaro violated exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists, a type of immunotherapy, and failed to use commercially reasonable efforts to obtain optimum commercial return for its immunotherapy called Jemperli. A trial is now anticipated in July 2026 and milestone and royalty payments continue to be due to Anaptys during the proceedings.</p><p>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it. Tesaro, in turn, alleges that Anaptys breached the agreement between the two companies. Anaptys said that Tesaro’s claims are entirely without merit and that it intends to pursue all appropriate legal remedies against Tesaro.</p><h2 class="st-heading-2">Previous Litigation</h2><p>Anaptys filed a complaint previously against GSK in 2020, alleging that GSK’s planned trial of Zejula in combination with Merck’s Keytruda violated the exclusivity obligations under the 2014 deal.</p><p>The complaint resulted in a settlement that included a cash payment.</p><h2 class="st-heading-2">$100M Stock Repurchase Plan</h2><p>Separately, Anaptys also announced that its Board of Directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100 million of the company’s outstanding common stock. This is in addition to the $6.4 million that remained as of Nov. 20, 2025, under the current $75 million stock repurchase plan.</p><p>The shares may be repurchased from time to time in open market transactions, and the stock repurchase plan will expire on March 31, 2026, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ANAB stayed within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.</p><figure class="image"><img style="aspect-ratio:584/61;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkgAAAA9CAYAAABWbpb0AAAQAElEQVR4Aex9C1RUV5b2V1BYxUMoUJCKGCljTCCmI0YzSneSJXlMC0N+gyYx8MesFvWPYvJ32nS6p+PYaZfpWR210x0FXSpm6WrsGBXTw4hZsYMrbQuaqPgKqNEpjJiqgFIl8iikgDn71oMC6snLQnete+49d5999tn3496PfR63KqCDP4wAI8AIMAKMACPACDACXRAIAH8YAUaAEWAEGIE7DgG+IEagbwi4DJBu3WqF0XgTNTV1+P77Wk6MAd8DfA/4dA8QdxCHEJf0jaZ61iabZJvaYH5ifuZ7gO8BX+4B4g3iD+KRnuzSKXEaIFFFg6EecrkckZHhUKtH4p57ojkxBnwP8D3g1T1AnEHcQRxCXEKc0kk73uVcaZEtskm2qQ1qi/mJ+ZnvAb4HvLkHiC+IN4g/iEeIT1xxTUD3guvXb0iimJgohIUFIyhIDplMJsl4xwgwAoyANwjIZDKJO4hDiEuojo1bKN/bZLNBNsk281NvkeR6jMDdiYBM5j03dQmQKJIKDAyASjWcg6K7897px6tmU4yABQGZTCZxCnELcYxF6vue6pIN5iffseMajAAj0BMBmcw9N9kDJJqLa2m5hYiIsJ5WWMIIMAKMQB8RIG4hjiGu8dUU1aG6ZMPXuqzPCDACjIA7BIhXiF+IZxz17AFSU5MJoaEh9pEjRyXOMwKMACPQVwRkMpnEMcQ1vtqiOsxPvqLG+owAI+ANAjKZc26yB0gUOSkUQd7YYh1GgBFgBHqFAHEMcY2vlakO1fW1HuszAk4QYBEj0AMB4hfiGccCe4BkNrdBLg90LOM8I8AIMAL9igBxDHGNr0apDtX1tR7rMwKMACPgDQLEL8Qzjrr2AImEMhm/rUY4cGIEGIGBQUAm6z3HyGTWugPjGltlBBiBuxgBmawnv3QJkO5ibPjSGQFGgBFgBBgBRoARsCPAAZIdCs4MEgLcDCPACDACjAAj4PcI+HGA1IaaK7Uw+z2E7CAjwAgwArcLgWqU7j2CK7ereW6XEbiDEfA9QOoGRmPlfmxdtwHr8kTauBslF5u6aXh/em7fTpTWWvWNX+NAYQm+MlrPB+pQewQF+y4MlHW2ywgwArcJgZrDO5G3+XOca3dw4PKX2LpxZyfPOBTd7qz5VBHyiiq6uHHj6G5sO6jvIut6YsD3VXrUdRXyGSPACPQDAn0LkNrPYP/n9Xho/mK8vkSkzCTcGxzSS7fqUXe9BSaztbpqGrL+/0tIVlnPB+pQZ0Bdc8tAWWe7jMCAINDR0YHr1+tw9aoOFy9WoaLiPE6d+gbHj5/G0aMn8NVX5Thx4gxOn65AZeW30Gq/g073A27ebBgQf/zRaFtLC+Qd1Th7ptO7c6cvwwQHnuksuu05+QQ1Iqou45zdk3p8c96AGE2sXcKZgUWArfcdAUFNaBb/U2/ebILBcBPXrhlRU1MHvf664KBaka7hhx+uo7bWIDjsBm7caEBDQzO6v2Lfd0/6bqFvAZIgoC6hRfh9GD/a6lS7Aaf2bkfexs3I27QbpVctcholKjl5GB9v3ox1f96MglJL74jkxw31+Gav0JdGdC6gaON+K1mI/F9KcLRkNzatX48PqFf4QwWKtpGNDV16WI0Xv5Rs5+VtxlZhp5GapVGiomM4u0/4Y6vfLApIfuASzFf/Kfz0z16l8JI3RkBCoLXVjPr6RolYiEwo6Lly5XtBQNeFvEGQkgmtra3oEAzV3t4uCOcWmpqaBQHVC0KqxeXL1dKRfs/MIJ41IjHSlYzfoTt5eDjqvj1jubr2CzhXE44Yxz5c4yWUfLxVPP+Cd/IF30iEAegOC64RHJK3cSs+PlQtTfU7k9Wd3I9tgsvy1osR9O1fQmcbrbp6xMJDxH9S2mkZtXLRnuRg8ARoIqqhrZLOgOYL0N6IgyZenNv4lHzK246iSicj9cRnfzmCGqFOG42gFRy2DMlTvujwGXz6EXEm8W41rhzaja156/HBxiKcsl43bO2Qzw68TfY4MQKuEOjKTbcE59wUnbFGiZOIq+j1eeIkQU0SP7W1tQuuMoO+vbqxsVniLzr6Gzf1LUAKnoKUKcBXWzZj275juFLfCd+5fbtxPOJZLHltIZY8r8a3XxwB/QxuS3Mtzl2OxMzshXj9lUSYj5dLQdCDael4KCwcDz0v9NMmCEMtaBFRqCUAE/naatTcm4pFS5diZswl7P9vPSZlChsLpkJ++mucFTVQdwS7PzcgQciXLJmPx259iZLzosAs6ledR92PsrDEWv/oCeFs9DRkPR4HjP6J8FOMVkULXd4YAT9DgMilrq5eCowaGpqsxNKKiIhwnz0NFwEDkRIFRxQkUc+uURAUEZfPxvyughOHYu6DxnAex6lDdF5wwOg4RLXa9Awo3VOCuoS54vlfiEXTzCgpuSAKK3D0GPAvxF2vzcecaXGQw5kMUKiTMEtw2ZKli/FMRAU+LxO8glqUfFaBEc8KLhM2nh2jwJiniV9ctSealLZwPHRfCK5cqJbOWs5cQl38fXhQnJ3b9zGODxd8ukTYfDUJjV/sRWn3eTXiOdFpbRP6tNEIWkuL5YzyVZdb8MSrgjOJd48W4aiwN3/JUqSP0eP4V5ZA6pwL3iZ7nBiB7gi44iaFYlh3VY/nw4YNkwImf+KmvgVI4pLVP34Jr7+Wjok4jyLRO7GMCF2G9mogopQ6HD9RjuNXzFA06GHrGMXEJyKCWo4KRyg91PDmE457x4dIihHDQxGhScSYIHEaqoCivQ1EAy0XL6Ne/AMwnxdtnjiNlmEK1F61jFAhJA73jwkUFQCq39bipAcmlfKOEfAPBNra2sQQdb00PG0yWboKNs8oyOlNgBQaGmwzIR2pJ0dD3BQoETFJwjtqp8bE+5rw7TdNOHfBgDEJokNku77mS2KEJhwRbSKAEjx1qlkOZY0OOsRDM9qAo7u/xFldC+TEM05lQOioaLRVlaNkXxFOXgMsvEJsJHhpOKRPYGAL6uvE389le5KatItIiIfiyiXhA3DuuzrET6DOIvFpKOIfsU61hT6MSWProb0obEq1vNuFxorg0Ma7UOP+SeFSxdBgBdBBPlM7gS55W1LmHSMgEPDETb0JkALo3hS2bZs/cFM3l2yu+XhUxOLRNDE683/GovH0aWjRAnOro41w3D8tCWMcRQOQN4kpiC5m1Q/jsQciu4j4xH8RYM86Ebh5s1FMh9WJIWrn/wRpSHv48LDOCl7kgoOVMJvbnWraCI/WC1Cv0KnSEBWqJ92Hlguf4+yNsZg41uEiWswwO5wiIBaPTHsAUQjBI3PEyNGUUGg/F9PyeysEozmTiRGhv2zF/osK3P/4s3hSE2q1Fot/SVLg1J6d+HTvThysmSBG2hWAy/as1egQdZ/gyWpo687gW3087n+AhMSngVAGUb4zmVud3xudGr7mqB3HOoPD244tct7/EfCGm4KC5D5diFweiFu3ujyN9vq3k5v6FiBdPYZ/fENDyvZrAYIUUGIs7oluQqP8ATw6OcmSJo0VxOOg5zRrhpiadFrijTAiTg1FkxlRk2xtJmHiaIXnqs7/Z3iuxxqMQD8jQMFJba0BtMDRk2mZTAaFD0PZNOJEI0/u7NJ6AWq/UUy7udMbUmVRidC0VqNR8yOoHR1XxeEeRSPMUVa+IK5KiIUCbaKDF4iocVOQ/uo0xHx3Cd86lVXje4PoHD4rRrPDFWhstgUs9ThV0YZHZ8/CjKdmYf68J6EOEA27bE+U2bdYJGjaoC25hJoxluk1SHxqgPZCk0WrXYz06BS4J84yAmQRiv0oEdo1GFAj8VkTaq41CqEv29he8rYvbbDuUEXAF26ioCYwkG56766WeMwfucn7K3B2napImE/txLr1m5G3cTPW/XctNE9NEySkwKPpzyL81Dbkbf8Uu7dvxaZ9F2CjD2emgFgkjJPjbKGw9fGR3r22OjYF6Q8ZsD9vOwpEz016nfe689bsUjGEran5Eus2ip4grVeyF3CGERhcBCg4uXbNIK0x8qbllpZWn9Yh0fojIjlPtmnhNk27GY03PakOkfJIPDF3HuZMi+zmbxyeSUtE3WcbsHVHEQryN6PgiAGoLcfuj7Zi226SHUHjj6ZiojMZ4qCJ1uNA/k4UbCtAZXOI1X44xsQ04ugOwUMi5X20E0WHLqFR6DttD10/6vvi0HhFh3sEN1lKHPm0AFvzPkfdQ6l4RhoNi0REaDWOH9IDARMw8V4dSmgh98a9qAmNslT3eu/Yjre87bVxVhzCCPSGmyjo8faSg4KCxOg2TfO6rzHY3NS3ACn0PqRkLsTr/y8LWZnz8PrSLDwTbx2xCZ2A9IWLsWh2Cma+PB+L0ieInhnE0PVSzHkE1s/DmPPmLNhO1TPm4c1F87Bo7jQx2uRY5pgH1CnzMD/FOh+PbmU/fglLlryEf6OemzgmjxBNqZ/E/GzRixNZ2rrUD07ErKXCz5/Nx8wHqJQTIzD4CND6H5ream/v8LrxlpZbXgdIMpnMp9EmcqKpySS9hkukROdDLXV5zhXhCJWmqGKRkj0PKbahpNHTkPXaYmT925OY87OFyEoWQVT0FMxdNB9ZM5/ErHkL8eqMWMCZDJF4dO5CLHphJua8koX0OVkWXmq/gJNX4zCLFlS/JspfnAblhcM4qhMIOmtPiLtsoqO36M3FmJXgILXzaTqyhN2sHwufpGIR5C1YjHnSuQITn1+MJfNeQvYiwcVpL1n8EXpdsOjOmY58am8npQtvCxN393YXX31vucmXAKmjQxr29BrlweKmAK89cqcYFIIIMcTsTEUeaiMmZ6VOZAoFfJu9dGIjQOHSHzj9BIp/HuAPI3BbEKDpLHqjzNfGaRFjRMRwxMffi/vvH4eHHnoAkyZNxGOPJWHq1El45JGHkJg4AePHazBu3FjQsLevbVAQRq/edtyxr7lZEFGEh0PRjQ2dcZczWY+6LY1iuq0JdcY2yXhbvQ41bZGIUUmn0q5HHUnqeUftd/cTAYGQO/jeW9uOrVM7loDSUcr5uw2BvnCTQhGEiIgwREaGY+RIFWJioqBWj5QS5UlGZSrVcL/lpoC77Q/O18sI+BMC1BOi6SxffAoJUUqEQ2Qjl8sRGxuNESMiMXx4GJRKBQICAhAYGAhalB0ePlzoRiE6egTCw8PEMRJhYSGiPMDrJml4nYIkryv4n+LgehSchDmzx6Lmy2J8urcI+0/JxRRfOiYGD64b3Boj0BcE+spNxEP01mxwsALDhgWBFmLLZDLIZDIpTzIqIz7zV27yniX7gjTXZQQYgR4I0HogX4IjGrIeNSoK1OMiculh0AtBUJBcBEqhGDXKEjDJZDJ486Egib6k0htd1gHko5Iw8/l0zKL00ykYE86oMAJDBwHmJsvfKsBy4D0j4McI3IGu0ZRVXd0N6VtlPV0e9cQiI4eLUaIIMfIT6End6/KwsGAx7B0pppeHeVWHvqSSpty8UmYlRoARGJIIMDd1/tkCOrOcXehWbAAAEABJREFUYwQYgcFCgEaOqJfmqT25PFCaFqPpMk+6vSmnqbgRIyJAQ+He1DcYboLWPnmjyzqMACMw9BBgbur8mw1GgNTZGucYAUYA7e3tMJlueUSCptGioyPFqNHAP6a0mNKbIIl8b242efSdFRgBRmDoIUDPN3NT599t4Jm3sy3OMQKMgECARo5GjYpyO2pDwRGN7Mhk3q0REmb7vHkKkmhB+IgRKtCiyt68EddnB9kAI+B3CNxZDt06cwqjYiKZm6x/Vg6QrEDwgREYDAToJ0Lo+44o0RscMTFR0hsejm0HBgYgKipCetvDUT4YeQqSaDG4Y1sBATLpdd3oaJX0Y5I//FCHGzd8/ZZmR4ucZwQYAX9DoKXyG3z36lxc+b9zoPjuEpibgD4HSKZreuj1RnQZdG8w9pTdxruh5BdqqMe8hZLb6AM3zQgQArafELEFSvS7RpGR4SIgChdTaZYF2HROQQnp344UFRUuvYZLbdO0W0zMCClYox+0pYXatIiTfjyXRsJIx2+TiXiI+MkxCa4yd3rs/7kSvDVG8NcvfGQv67UbTf5/heyhfyBwfVOe5IipQgRK817CtRW/ggqtdzU39TFA0iJ3hnh41Rq89U/YP9oNyVCrc/olINGuToTs4bXQ2q37npGCuGpd1yDOdzNcgxHoEwIUUFBg4WikubkFFHi0traBRmhoWo2m1xx1Bjsvk8kEKUaIHmQkaJTr+nUj6GdHui/OpmBpsH3zqb0DOYKH1N1SMnKr3FspnieDbF6xe6VBKzVBVy0CvGs+RjrWa885MGiOckNDGIFb/3MRDQf/3nkFHR2oLy6CNu1pNG7PR3REiPQW7d3GTX0MkGx4GpG7uG9BjM1S96P+Sl9Co+7WnJ+/++67ePHFF50XstSPERhartEXrznzmEZkaCSpttbQY7rNmb4zWXV1NRISEhAaGorjx49LKn/4wx+kkR+ZTPzDd0gklxTc7OjtOVqsSVOBra3Oh1wouCPf3Zjxi6KM7TrodLZUipx4d27pRUDirpzLXCHAPOoKGf+X3/hboVMnO1pMuJ73Z1Q99yyCzJ5fLHE08vXXX0ucJJNZ+OdXv/oVWltbJRXijQsXLuDnP/85QkJC4A0nSRXFbjC5qV8CpIT0VGjOvoWlfzUK951sZiOKfzEZwVag1Kn5qDRb9KTpr9Rc+wiRdkOamA5Lk3p5VJa6QfSczi5HssMwM8nVbxSj8oNkyWbi6lMoW5eFyZEyyz+EIDVmb660NODFnh7sxMREDpK8wIpVeo+AqwDJZpEefJlMZjv1+khks2bNGly5cgUKhcJe77nnnsOuXbvsaf78+dJoyuzZs+067jJBQXJ3xdJ3OFEQ5VbJDwqVqljExtqSCkpzGZZPFSNLz1p5R5y/laDG5Ld34E+pSVh6EMBfswQPqZG2QStOLNNcS4sqsfbxYMExiVh7UYivFeOtJDqXCZnQtXOORX/B5hKsTVWLMlGuTkP+OT12zLOeByVj7Tlhw7a5tGVToKMWuSnC74x86OmUUkMhFghuTNtsl5DUfTJ35ePgpLdQfM1ShThVPWYBChss58VviPbGPIVcul4hsvDzAhSbxEm3jXm0GyBD5ZRGi4o+devtsHgNAkLD3Oo4FjY2NuK3v/0tZsyYgaqqKuTm5oI4avv27ZJaU1MTVqxYgR07dqC5uVmS+bIbLG7qlwCpUpWBVelA8ZLlKDP3vMzyFZOR9oERWZ9UQHdmC5LLFiD57TKQpumaHvorDk9bgxb6ai1Mwk5iZi6ypwmt2Aws/2MucjMTxQkg1VmXhsQ8NVZt34OCl8dCe6gSk3+/Dye+3od3HjeicNFS5PvAGfxwS9DyboAQoG+ipldo3ZkPCwt1V+yy7O9//zu2bduGBQsWoKWlxa6XkJCAOXPmSGnKlCn4xz/+gffffx/jx4+367jLKBTD4ImImofAK//aQ4Uo3GVJJecE1yinY/nKNJgOLJU6dfoNy0SwkoicNzLwr28uR0asQGVaNnIF5yyboRYnlmmu3OcSkatehYJPCpAVXy6CrDSsbcjCnjM6VGxNRumiZLx1BOJj0c9fNBvFU9Ziz/sZUOmLsSBBg1XK5dizPQdJFJS9vQPCG8DszpYwZ980mP28Bvq9+dhTbRGaivKRX61B6kxy2iLztLfwsRap738h+HI9UqvWIm3qcpQLzk2YOhnG6nwUHyIr5SjdJfi5ugSFB4lMTSjbXwz9/dMxWUnlPRPzaE9M/F3SfOJrtNVdd+tm1KIct+XdC2kku6ioSAqMxo4di+effx5xcXESB5EulX/88cfYv38/aASJZL6kweKmfgmQADUyV7wDjVEENB9ou11nMXL/U8heXoVVj0cCI9OQs1AD44FS+6hRtwr209gpGUjRiNORk5H6QgYypjiSwHSsP7gHy17JQFKcCpmfnMCWhSnQjFQjeUqSqFSCsnJx8GHjh9sHsFjVJwQ8jbTQm2v0444+GRXK169fxzvvvIO5c+fiiSeeEJKeG40w/elPf8Lo0aMxa9asngpuJCEhLv4TWuu0tFiGzK2nfnkoWz0bs1+0pKVFOslH5cw1yH9ZieLfpCD17TIkvL8F2XFKJDyTiskjhYomBRmCc1IedLj+aetR+skyZL6QhNgDuXivCshcuQrJQj9yZg6y440isBBcJ6pL2ysF+GJlJjJ+uQpvPSgkE1dh36YcZLyyDFkTxblWB8kbb2wJddpif7YUGShDwV5LwFK4qxiYkY3ZcVTqTbLycXouCn6ZgqQpOSjISwWq3kPuAVF/mrhucSg9WSlkJSjWpyDlGaDkYKmQioBJ6MROmwxHJhYFXTbmUQmOIbNrLHVYQOzEa/moWIRMecxJiXtRYGCgNHpKWsRT9fX1SExMpNN+SYPBTf0UIInrnbIc619RonLFchQaxLltu1gJerSkIWu1GK4V6anVDiRi0/P5qIHGTgpGlK1OgzooGJEJqcjeXCZZazZLB94xArcdAVfreGyOeXrYbXqORwp8Nm3ahJs3b0pBUlBQkGOxPV9VVYXdu3dj4cKFCAsLs8u9yXj6Bm/ygRafe2Prdulk/lcHyE9KFb+kHhd5okLGGzlQVZWLkZNsrH/TJqcyF+l+jT0w0J6VWA07Mi2cplY/hbVVLupBCaXcVRngk62wTOQsVqJsUwG05hLs2wukvJwGdwFLl5aNOqljmvD4dNhCP+XUFCQIpdKzgpflyUiZAVRSB7asBOWx07HshRRgr+hwXixFiUmJ2WIaEvy5YxAwfXPW7bWEP5fhttxTIa07+vDDDxEcHAxvp/c92aTy4GDbHUxnPRM9733lpv4LkMTjlvr79Ugx7cCeg6pOb8cnIEmcKRd/YScpcrzjzDJohFzarhlgRB8+/1yOlLeLkfjh/4j5TNEr257ZK2PU86moqMAnn3zSq/pciRFwhQCRhKsyktOQMR19SSdOnMCqVaukhdkrV67EunXrxP3fLMlOnjxpN1VaWirJJ0+ebJd5m6GvGwjysBbJ07V529bg6umR/5u1MM0QwYE5H+99pO/avIczzYMSqyGnpDP4Il7rDMA8GHAo9tVWSmY2lGfzUfhRMQohOoQvex0eASq1xLuV5eWdHlSegBgvQvJEYuRYpMwU4dLBMuSfOQHMEKP3SdMRaypF6d4TQi8DKbTsobN2jxzzaA9I/FpgOnvarX+hyT9xW+6ukJ6JDz74AB999JHET95O77uzaSsbDG7qxwBJuB2XjTX/rkHZEcsIjpCILQVZP1PBtGEBFuyqhF6vh/ZYIUqsi/4iVUpAX4iCg1poDy5H1m/oURXVbBv1vAQZ7Dgm5sJdfanHTRNMUCJWDHUb9ZXIF8Rhq955NMHoqr5Qevfdd8HBkQCCt35HgF6Pb2/vcGvXUxDirLLBYMCIESNQU1ODzz77DMeOHZM6IYcPH8a1a9fsVQ4ePCgtUo6OjrbLfMl48q21tc0Xc4Ou67gGqXBXIcqrAeNfs7HgYAJWbfoC+a+rULIoGztsvTRBSdhVgB1Vehiti5V7OD0jC9kqE3IXLUDhWcFNei3Kd5VIozM9dD0JvLFlMsJOXz/JwbL4Six/Ix+m9CxkhLluoOu1l0NPAZW4Xvx1FZYf1EJfVYLlK3cAqmxkPG6xo5mRgVjsQe4GPZKmJgGTxKgSypG/VQRVM1KQLLfoOdszjzpDxX9l5h/0aG+46dpBmQyKB3s3LUbBEa2N/N3vfgcKkjIyMly308uSgeamgF765bJa0m/WI1PpWKxE6qZSbJnZjPwXE6W3aMZNzUFumVZSmv7GGkyXV2JtyjiMyyxH9u+7jv6kvm0pX05vnbxYACOcfJ5ZhjXTTGK4e5ywn4LC+FRpyNimmfJyNlSir5W1pBjOPvHx8RwcOQNm6Mr8yvP29na3/sjlnXP1bhW7FT799NP47rvv7InIiBY80sJHKiN1epukqqoKFBwplV0eTCr2KnkiIU/X51UjA6jkuAaJ1iKt+WchcuYXQ/nKGuSMB6avzBecVYyseTtgFOMr2SuyxYjJDmRpxGjLCsfOHjo/YanYUrYFqQ35mP2wWvDOOEx+IxdlVZ0qXufc2kqROpjYlYWc/TaLCVj6i+kwmUzIeDkD7v6qXa89CwWiYzr9j8THOrwnOFeteQrvVVuvxRZoTUlGGowwGpVInqoB5JMt027nKpEwMwWxcP5hHnWOiz9L2wx1bt0bdu9YBIipMbdKTgopOKI317Kzs/HTn/4Uo0aNwp49e6RF2fTWWl1dHf72t7+BXjC5desWTp8+LZ2T3Ik5l6KB5qYAly17VaDBsjMd6Nie2qktHvaCZiHrKIBdKk9AdrEOHTcN0OkMaG7VYc8r4sGjWuNzUNrcDAPJdfuQ/csC0QuuwDJBXFSMB5d1ln9OgQ6Qur1D6BR0sb+srAPNtToYmnXY98cCVHR0oCBdsgDlzC0wiLYNm5xHsFVVVTytZoGK9wOAgKcAIiCgj4+hG5+pbXqzbeTIkehtgBQY6N4/asONC7evKJ24pENwRddUMDcDxFHNgreUEB9VhnTe8V+ZUAFQpW+BrllwVW0zDH+cLiSpKBB80oXnhBQPZmOfzsI7OqHboduDzHgq6K6vsfCkfVlB93NRx6Ut0cHcKjiz1oB8K58JbeuWgdnpSmu+28HptVdYeNWRjyW/9yGbFpHbTYiAia63oxnrpdmVWGRbpxLdTSEyj9oBHDKZths33PoaGBnlttxVIc0UrV69GsQNhYWF0lfovPDCC3jttddE4G2EVqtFZmYmfv3rX8NsNkuv+9M5yV3ZdCYfaG5yz3zOPOqLLEyF2FhVzwWLciVUJIf10/3gqdyqrxwZC5ULvkCYCqowqyIfGIFBRKDdw/RaQICsX7xJT08HjRg9+uijdnvDhw/HoUOHpEXacrncLvclExDgnibaPYyQ+dKW3+gqBVeNVHrljnJkrJje907Xk0FXtpQjVRbevFiC3NWzkfxGGYDoCosAAAN6SURBVDT/vhyZfeG0MO+v0ZPfXD40EWirr3freECEym25q0K1Wo3Lly/36JyQjMqIo4iraKTJluic5K5sOpMPNDe5Zz5nHrGMEWAEfEKAfq7jnnui4SpFRUX4ZG+wlennBVz5TvKRIyMH26W7tj3tgbVY9WElNP+xDydWJt21OAzlC/cn34c/86+YcPK8yzT6zxv8yd0evgw0N3GA1ANyFjACjAAj4J8IaBbvg+5KBb5YmQpV7wYE/fPC2CtGwA8RCPBDn9glRoARYAT8FAF2ixFgBO4WBDhAulv+0nydjAAjwAgwAowAI+A1AhwgeQ0VK94JCPA1MAKMACPACDAC3iDQJUCi1eTeVGIdRoARYAR6g0BfOKYvdXvjK9dhBBiBuwcBZ/xiD5Doy+rMZv/+Rlzg7vlj8ZUyAnciAsQxxDW+XhvVobq+1mN9RoARYAS8QYD4hXjGUdceINHrci0trY5lnGcEGAFGoF8RII4hrvHVKNWhur7WY31GYMggwI7eVgSIX4hnHJ2wB0ghIUo0NjZJX+zkqMB5RoARYAT6AwEawiaOIa7x1R7Vobpkw9e6rM8IMAKMgDsEiFeIX4hnHPXsARJFTgrFMNy40eBYznlGgBFgBPoFAeIW4hjiGl8NUh2qSzZ8rTtI+twMI8AIDFEEiFeIX4hnHC/BHiCRUKUajra2dhiNN3kkiQDhxAgwAn1GgHpnxCnELcQxvTVIdckG2SKbvbXD9RgBRoARIASIR4hPiFeIX0jmmLoESFQwYoTlZw9qaurQ0NCM1lYzB0sEDKc7GwG+un5FgIiHuIM4hLiEjNu4hfK9TTYbZJNsUxvUVm/tcT1GgBG4uxAgviDeIP4gHqGrt/EK5R1TjwCJCimSiowMh9lshsFQD53uGr7/vpYTY8D3AN8DXt0DxBnEHcQhxCXEKcQt/ZHIFtkk29QGtcX8xPzM9wDfA97cA8QXxBvEH8QjxCeueMlpgETKNBdHFWNiolz+yCb9UKWfJPbxnmjGgDHwq3uAuIM4hLiEOKU/E9kk29QGcxA/+3wP8D3gyz1AvEH8QTzijpdcBkjuKnEZI8AIMAKMACPACAwGAtzG7UKAA6TbhTy3ywgwAowAI8AIMAJ+iwAHSH77p2HHGAFG4E5AgK+BEWAEhiYCHCANzb8be80IMAKMACPACDACA4jA/wIAAP//rAswPAAAAAZJREFUAwALSJh3aBPUmgAAAABJRU5ErkJggg==" width="584" height="61" alt="ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits"><figcaption>ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure><p>ANAB stock has nearly tripled this year and gained 78% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/foxconn-to-pour-up-to-5b-into-us-plants-after-striking-servers-deal-with-openai/cLPMZruREOB">Foxconn To Pour Up To $5B Into US Plants After Striking Servers Deal With OpenAI</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

The dispute centers around Tesaro’s participation in PD-1 trials. 

Glaxosmithkline plc - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$48.28
Prev Close	$48.64
Open	$48.68
Dividend Yield	0.00%
50-Day Moving Average	$51.93
Beta	0.86
Avg. Volume	596,211.65
PE Ratio	7.55

52-Week High	$72.36
52-Week Low	$20.18
Market Capitalization	$1.45B
EPS (Annual)	-$0.4601
Price to Book	136.61
Revenue Per Employee	$2.26M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANAB Fundamentals